Aiolos Bio
Biotechnology company focused on developing therapies for respiratory diseases. Acquired by GSK in January 2024 for approximately $1 billion.
Location
Waltham, Massachusetts, USA
Founded
2023
Categories
biotech, respiratory, immunology, acquired
Notes
Aiolos Bio was a biotechnology company focused on developing innovative therapies for respiratory diseases, particularly asthma. The company's lead program, AIO-001, is an anti-TSLP (thymic stromal lymphopoietin) antibody designed for extended dosing intervals.
Acquired by GlaxoSmithKline (GSK) in January 2024 for approximately $1 billion. The acquisition provided GSK with AIO-001, which has potential to be a differentiated anti-TSLP therapy with a favorable dosing profile compared to existing treatments.
Team
- Richard Kendall - Former CEO
- LinkedIn: linkedin.com/in/richardkendall
- Leadership team from Bain Capital Life Sciences portfolio
Additional Research Findings
- In Bain Capital Life Sciences portfolio prior to acquisition
- AIO-001 targets TSLP, an upstream trigger of inflammation in asthma
- Designed for subcutaneous administration with extended dosing intervals
- Technology aimed to compete with Amgen/AstraZeneca's Tezspire
- Acquisition part of GSK's strategy to expand respiratory portfolio
- Deal valued at approximately $1 billion upfront plus potential milestones